Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Trial Profile

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Lewy body disease; Neurodegenerative disorders; Parkinson's disease; Progressive supranuclear palsy; Vascular dementia
  • Focus Adverse reactions; Registrational
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top